These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 32418275)
21. Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients. Ladfors SW; Lindahl JK; Hansson S; Brandström P; Andersson R; Jertborn M; Lindh M; Woxenius S; Friman V Pediatr Nephrol; 2020 Mar; 35(3):427-439. PubMed ID: 31802220 [TBL] [Abstract][Full Text] [Related]
22. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Styczynski J; Einsele H; Gil L; Ljungman P Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376 [TBL] [Abstract][Full Text] [Related]
23. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054 [TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Ellis D; Jaffe R; Green M; Janosky JJ; Lombardozzi-Lane S; Shapiro R; Scantlebury V; Vivas C; Jordan ML Transplantation; 1999 Oct; 68(7):997-1003. PubMed ID: 10532541 [TBL] [Abstract][Full Text] [Related]
25. Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study. Ville S; Imbert-Marcille BM; Coste-Burel M; Garandeau C; Meurette A; Cantarovitch D; Giral M; Hourmant M; Blancho G; Dantal J Transpl Int; 2018 May; 31(5):484-494. PubMed ID: 29057508 [TBL] [Abstract][Full Text] [Related]
27. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Smith JM; Corey L; Healey PJ; Davis CL; McDonald RA Transplantation; 2007 Jun; 83(11):1423-8. PubMed ID: 17565314 [TBL] [Abstract][Full Text] [Related]
28. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716 [TBL] [Abstract][Full Text] [Related]
29. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. EBPG Expert Group on Renal Transplantation Nephrol Dial Transplant; 2002; 17 Suppl 4():31-3, 35-6. PubMed ID: 12091638 [TBL] [Abstract][Full Text] [Related]
30. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience. Wasson S; Zafar MN; Best J; Reddy HK J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222 [TBL] [Abstract][Full Text] [Related]
31. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT. Kinch A; Hallböök H; Arvidson J; Sällström K; Bondeson K; Pauksens K Leuk Lymphoma; 2018 May; 59(5):1172-1179. PubMed ID: 28831836 [TBL] [Abstract][Full Text] [Related]
32. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease. Verschuuren E; van der Bij W; de Boer W; Timens W; Middeldorp J; The TH J Med Virol; 2003 Feb; 69(2):258-66. PubMed ID: 12683416 [TBL] [Abstract][Full Text] [Related]
33. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients. Liu M; Husain S; Famure O; Li Y; Kim SJ Prog Transplant; 2019 Jun; 29(2):185-193. PubMed ID: 30845885 [TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders. Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146 [TBL] [Abstract][Full Text] [Related]